학술논문

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2
Document Type
article
Author
Silvestri, ValentinaBarrowdale, DanielMulligan, Anna MarieNeuhausen, Susan LFox, StephenKarlan, Beth YMitchell, GillianJames, PaulThull, Darcy LZorn, Kristin KCarter, Natalie JNathanson, Katherine LDomchek, Susan MRebbeck, Timothy RRamus, Susan JNussbaum, Robert LOlopade, Olufunmilayo IRantala, JohannaYoon, Sook-YeeCaligo, Maria ASpugnesi, LauraBojesen, AndersPedersen, Inge SokildeThomassen, MadsJensen, Uffe BirkToland, Amanda EwartSenter, LeighaAndrulis, Irene LGlendon, GordHulick, Peter JImyanitov, Evgeny NGreene, Mark HMai, Phuong LSinger, Christian FRappaport-Fuerhauser, ChristineKramer, GeroVijai, JosephOffit, KennethRobson, MarkLincoln, AnneJacobs, LaurenMachackova, EvaForetova, LenkaNavratilova, MarieVasickova, PetraCouch, Fergus JHallberg, EmilyRuddy, Kathryn JSharma, PriyankaKim, Sung-WonkConFab InvestigatorsTeixeira, Manuel RPinto, PedroMontagna, MarcoMatricardi, LauraArason, AdalgeirJohannsson, Oskar ThBarkardottir, Rosa BJakubowska, AnnaLubinski, JanIzquierdo, AngelPujana, Miguel AngelBalmaña, JudithDiez, OrlandIvady, GabriellaPapp, JanosOlah, EdithKwong, AvaHereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON)Nevanlinna, HeliAittomäki, KristiinaPerez Segura, PedroCaldes, TrinidadVan Maerken, TomPoppe, BruceClaes, Kathleen BMIsaacs, ClaudineElan, CamilleLasset, ChristineStoppa-Lyonnet, DominiqueBarjhoux, LaureBelotti, MurielMeindl, AlfonsGehrig, AndreaSutter, ChristianEngel, ChristophNiederacher, DieterSteinemann, DorisHahnen, EricKast, KarinArnold, NorbertVaron-Mateeva, RaymondaWand, DorotheaGodwin, Andrew KEvans, D GarethFrost, DebraPerkins, JoAdlard, JulianIzatt, LouisePlatte, Radka
Source
Breast Cancer Research. 18(1)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Oncology and Carcinogenesis
Breast Cancer
Cancer
2.1 Biological and endogenous factors
Aetiology
Adult
Aged
BRCA1 Protein
BRCA2 Protein
Breast Neoplasms
Breast Neoplasms
Male
Female
Genetic Predisposition to Disease
Humans
Male
Middle Aged
Mutation
Neoplasm Staging
Polymorphism
Single Nucleotide
Male breast cancer
BRCA1/2
Pathology
Histologic grade
Genotype-phenotype correlations
kConFab Investigators
Hereditary Breast and Ovarian Cancer Research Group Netherlands
EMBRACE
Oncology & Carcinogenesis
Oncology and carcinogenesis
Language
Abstract
BackgroundBRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs).MethodsWe characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database.ResultsAmong BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis (P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage (P for trend = 2 × 10(-5)) and higher grade (P for trend = 0.005) and were more likely to be oestrogen receptor-positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15-21.80] and progesterone receptor-positive (OR 5.04; 95 % CI 3.17-8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database (P for trend = 4 × 10(-12)).ConclusionsOn the basis of the largest series analysed to date, our results show that BRCA1/2 MBCs display distinct pathologic characteristics compared with BRCA1/2 FBCs, and we identified a specific BRCA2-associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management.